How much is Medpace worth?
As of the most recent market data from July 24, 2026, the stock price for China Mengniu Dairy Company Ltd, which trades under the symbol 2319 on the Hong Kong Stock Exchange, was 18.10 Hong Kong dollars per share. The stock experienced a significant change of approximately 9.30 percent during the latest session. Throughout the trading period, the stock reached a high of 18.30 HKD and a low of 17.92 HKD, demonstrating the volatility typical of this major dairy producer's equity. With a market capitalization of approximately 70.85 billion Hong Kong dollars, the company remains a significant component of the consumer goods sector. The company has maintained a 52-week price range between 13.88 and 18.82 HKD, indicating a period of recovery and growth. Investors monitoring this stock observe various financial metrics, including a price-to-earnings ratio of 39.45 and an expected dividend yield of approximately 3.30 percent, which provide insights into the company's current valuation and its appeal to dividend-focused investors.
Related FAQs
Compensation for merchant bankers and corporate financial advisors varies extensively depending on transaction deal flow, firm size, geographic market, and performance-based commission structures.
Medpace operates strictly as a scientifically driven, full-service contract research organization (CRO) providing comprehensive global clinical development support to pharmaceutical, biotechnology, and medical device companies.
Equity research analysts tracking Medpace Holdings (trading under the ticker MEDP) generally evaluate the stock as an attractive growth investment, though opinions fluctuate based on broader biotechnology funding cycles and valuation multiples.
Medpace Holdings is an entirely legitimate, publicly traded multinational clinical research organization listed on the NASDAQ exchange under the ticker symbol MEDP and recognized as a component of the S&P mid-cap index.
Medpace is a genuine, highly established corporate entity operating globally within the life sciences and clinical research sector.
Medpace operates strictly as a contract research organization (CRO) rather than a drug development sponsor.
Wall Street equity analysts frequently assign favorable ratings to Medpace, with consensus opinions often landing between a moderate buy and a strong buy based on its stellar operating margins and superior backlog conversion rates compared to indu...
Medpace is fundamentally an American corporation, maintaining its corporate headquarters and primary integrated clinical research campus in Cincinnati, Ohio.
Medpace is widely categorized by institutional investors and equity analysts as a classic growth stock, characterized by robust double-digit historical revenue expansion, rapidly scaling earnings, and high reinvestment rates into its core clinical...
Medpace offers a hybrid work model for various corporate, administrative, and data management positions, but many of its clinical operations, laboratory roles, and project management functions require regular on-site presence at its corporate camp...